| 1 |
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma[J]. Eur Respir J, 2014, 43(2): 343-373.
|
| 2 |
中华医学会呼吸病学分会哮喘学组，中国哮喘联盟. 重症哮喘诊断与处理中国专家共识[J]. 中华结核和呼吸杂志，2017, 40(11): 803-805.
|
| 3 |
Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children[J]. Cochrane Database Syst Rev, 2014，(1): CD003559.
|
| 4 |
Vennera MD, Sabadell C, Picado C, et al. Duration of the efficacy of omalizumab after treatment discontinuation in 'real life’ severe asthma[J]. Thorax, 2018, 73(8): 782-784.
|
| 5 |
Di Bona D, Fiorino I, Taurino M, et al. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study[J]. Respir Med, 2017, 130: 55-60.
|
| 6 |
Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects[J]. Clin Exp Allergy, 2014, 44(11): 1371-1385.
|
| 7 |
Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses[J]. J Allergy Clin Immunol, 2016, 138(4): 1051-1059.
|
| 8 |
Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of Dupilumab in glucocorticoid-dependent severe asthma[J]. N Engl J Med, 2018, 378(26): 2475-2485.
|
| 9 |
Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial[J]. Lancet, 2016, 388(10039): 31-44.
|
| 10 |
Ortega H, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma[J]. N Engl J Med, 2014, 371(13): 1198-1207.
|
| 11 |
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial[J]. Lancet, 2012, 380(9842): 651-659.
|
| 12 |
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma[J]. N Engl J Med, 2014, 371(13): 1189-1197.
|
| 13 |
Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial[J]. Lancet Respir Med, 2017, 5(5): 390-400.
|
| 14 |
Mukherjee M, Paramo FA, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab[J]. Am J Respir Crit Care Med, 2018, 197(1): 38-46.
|
| 15 |
Bleecker ER, Fitzgerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial [J]. Lancet, 2016, 388(10056): 2115-2127.
|
| 16 |
Fitzgerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10056): 2128-2141.
|
| 17 |
Maselli DJ, Keyt H, Rogers L, et al. Profile of lebrikizumab and its potential in the treatment of asthma[J]. J Asthma Allergy, 2015, 8: 87-92.
|
| 18 |
Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA Ⅱ): replicate, phase 3, randomised, double-blind, placebo-controlled trials[J]. Lancet Respir Med, 2016, 4(10): 781-796.
|
| 19 |
Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Respir Med, 2015, 3(9): 692-701.
|
| 20 |
Panettieri RA, Sjobring U, Peterffy A, et al. Tralokinumab for severe，uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials[J]. Lancet Respir Med., 2018, 6(7): 511-525.
|
| 21 |
Busse WW, Holgate S, Kerwin E, et al. Randomized, Double-Blind，Placebo-controlled study of brodalumab, a human Anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma[J]. Am J Respir Crit Care Med, 2013, 188(11): 1294-1302.
|
| 22 |
Cahill KN, Katz HR, Cui J, et al. KIT Inhibition by Imatinib in patients with severe refractory asthma[J]. N Engl J Med, 2017, 376(20): 1911-1920.
|
| 23 |
Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study[J]. Am J Respir Crit Care Med, 2013, 187(8): 804-811.
|
| 24 |
Busse WW, Spector SL, Rosen K, et al. High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects [J]. J Allergy Clin Immunol, 2013, 132(2): 485-486.
|
| 25 |
Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma[J]. Allergy, 2016, 71(10): 1472-1479.
|
| 26 |
Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies[J]. Lancet Respir Med, 2016, 4(7): 549-556.
|
| 27 |
Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study[J]. Chest, 2016, 150(4): 789-798.
|
| 28 |
Fitzgerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies[J]. Lancet Respir Med, 2018, 6(1): 51-64.
|
| 29 |
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma[J]. N Engl J Med, 2018, 378(26): 2486-2496.
|
| 30 |
Wechsler ME, Laviolette M, Rubin AS, et al. Bronchial thermoplasty：Long-term safety and effectiveness in patients with severe persistent asthma[J]. J Allergy Clin Immunol, 2013, 132(6): 1295-1302.
|
| 31 |
Pretolani M, Bergqvist A, Thabut G, et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations[J]. J Allergy Clin Immunol, 2017, 139(4): 1176-1185.
|
| 32 |
农 英，苏 楠，林江涛，等. 支气管热成形术治疗重度支气管哮喘的有效性和安全性研究[J]. 中华结核和呼吸杂志，2016, 39(3): 177-182.
|
| 33 |
苏 楠. 重症哮喘支气管热成形术适应证选择探讨[J]. 中国实用内科杂志，2016, 36(8): 632-634.
|
| 34 |
Knarborg M, Hilberg O, Hoffmann HJ, et al. Methotrexate as an oral corticosteroid-sparing agent in severe asthma: the emergence of a responder asthma endotype[J]. Eur Clin Respir J, 2014, 1: doi: 10.3402/ecrj.v1.25037. |
| 35 |
Bilocca D, Hargadon B, Pavord ID, et al. The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma[J]. Chron Respir Dis, 2018, 15(1): 85-87.
|
| 36 |
Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2017, 390(10095): 659-668.
|